Guggenheim analyst Michael Schmidt downgrades Arvinas (NASDAQ:ARVN) from Buy to Neutral.
HC Wainwright Finds ‘Synergies In Treatment’ For This Bipolar-Focused Stock
HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA…